77-57-6

Basic information

• Product Name: 1-Phenyl-1-cyclopentanecarbonitrile
• Synonyms: 1-Phenylcyclopentanenitrile;Cyclopentanecarbonitrile, 1-phenyl-;1-PHENYLCYCLOPENTANECARBONITRILE;1-PHENYL-1-CYCLOPENTANECARBONITRILE;1-CYANO-1-PHENYLCYCLOPENTANE;1-Phenyl-1-cyclopentanecarbonitrile,98%;1-phenylcyclopentane-1-carbonitrile;1-Phenyl-1-cyclopentanecarbonitrile, 98% 10GR
• CAS NO: 77-57-6
• Molecular Formula: C₁₂H₁₃N
• Molecular Weight: 171.24
• EINECS: 201-038-2
• Mol File: 77-57-6.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 135-140 °C (10 mmHg)
• Flash Point: 113.5 °C
• Appearance: clear light yellow liquid
• Density: 1.03
• Vapor Pressure: 0.00542mmHg at 25°C
• Refractive Index: 1.5325-1.5345
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Water Solubility: insoluble
• CAS DataBase Reference: 1-Phenyl-1-cyclopentanecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Phenyl-1-cyclopentanecarbonitrile(77-57-6)
• EPA Substance Registry System: 1-Phenyl-1-cyclopentanecarbonitrile(77-57-6)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-20/21/22
• Safety Statements: 36/37/39-26
• Hazardous Substances Data: 77-57-6(Hazardous Substances Data)

Usage

Chemical Properties

clear light yellow liquid

InChI:InChI=1/C12H13N/c13-10-12(8-4-5-9-12)11-6-2-1-3-7-11/h1-3,6-7H,4-5,8-9H2

Upstream product

• 110-52-1 1,4-dibromo-butane 
• 140-29-4 phenylacetonitrile 
• 110-56-5 1,4-dichlorobutane 
• 108-86-1 bromobenzene 
• 1309660-34-1 potassium 1-cyanocyclopentane-1-carboxylate 
• 28247-14-5 ethyl 1-cyanocyclopentanecarboxylate 
• 4254-02-8 cyclopentanecarbonitrile 
• 1556-18-9 cyclopentyl iodide 

Downstream Products

• 17206-41-6 1-(1-phenyl-cyclopentyl)-propan-1-one 
• 4046-09-7 1-(1-phenylcyclopentyl)ethan-1-one 
• 77-55-4 1-phenyl-1-cyclopentanecarboxylic acid 
• 21573-69-3 1-phenyl-1-cyclopentanecarboxaldehyde 
• 17511-89-6 (1-phenylcyclopentyl)methylamine 
• 4535-96-0 1-phenyl-1-cyclopentanecarboxylic acid methyl ester 
• 57554-20-8 Ethyl-1-phenyl-cyclopent-1-yl-formimidat 
• 4535-95-9 1-ethoxycarbonyl-1-phenylcyclopentane 
• 17206-44-9 <1-Phenyl-cyclopentyl>-isopropyl-keton 
• 41848-73-1 phenyl(1-phenylcyclopentyl)methanone 
• 17380-62-0 1-phenylcyclopentanecarboxylic acid chloride 
• 68983-71-1 C-[Bis-(1-phenyl-cyclopentyl)]-methyleneamine 
• 5296-89-9 1-phenylcyclopentane-1-carboxamide 
• 59358-70-2 1,1'-Diphenyl-1,1'-bicyclopentyl 

Relevant articles and documents

Palladium-Catalyzed Distal m-C-H Functionalization of Arylacetic Acid Derivatives

Herein, we present m-C-H olefination on derivatives of phenylacetic acids by tethering with a simple nitrile-based template through palladium catalysis. Notably, the versatility of the method is evaluated with a wide range of phenylacetic acid derivatives for obtaining the meta-olefination products in fair to excellent yields with outstanding selectivities under mild conditions. Significantly, the present strategy is successfully exemplified for the synthesis of drugs/natural product analogues (naproxen, ibuprofen, paracetamol, and cholesterol).

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017

Apatinib preparation method

The present invention relates to an apatinib preparation method, wherein specifically an organic solvent is selected to perform refining crystallization to obtain the apatinib. The method of the present invention has advantages of simple operation and low cost, and is suitable for large-scale production.